{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:02:03Z","timestamp":1793826123072,"version":"4.6.1"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.vaccine.2026.128680","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:04:22Z","timestamp":1778601862000},"page":"128680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Strategies to enhance DNA vaccine efficacy against emerging arboviruses: lessons from ZIKA and Chikungunya viruses"],"prefix":"10.1016","volume":"85","author":[{"given":"Smrithi","family":"Sreekanth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anismrita","family":"Lahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2026.128680_bb0005","article-title":"Chikungunya and Zika viruses: co-circulation and the interplay between viral proteins and host factors","volume":"10","author":"Wichit","year":"2021","journal-title":"Pathogens (Basel, Switzerland)"},{"key":"10.1016\/j.vaccine.2026.128680_bb0010","article-title":"A brief review on DNA vaccines in the era of COVID-19","author":"Shafaati","year":"2021","journal-title":"Future virology"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128680_bb0015","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat Rev Genet"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128680_bb0020","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.128680_bb0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.coi.2020.01.006","article-title":"DNA vaccines: prime time is now","volume":"65","author":"Gary","year":"2020","journal-title":"Curr Opin Immunol"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128680_bb0030","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1056\/NEJMoa0805715","article-title":"Zika virus outbreak on Yap Island, Federated States of Micronesia","volume":"360","author":"Duffy","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128680_bb0035","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3201\/eid2006.140138","article-title":"Zika virus, French Polynesia, South Pacific, 2013","volume":"20","author":"Cao-Lormeau","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128680_bb0040","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1016\/S1473-3099(17)30446-2","article-title":"Zika virus in French Polynesia 2013-14: anatomy of a completed outbreak","volume":"18","author":"Musso","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128680_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2017.07.011","article-title":"Mosquito-borne and sexual transmission of Zika virus: recent developments and future directions","volume":"254","author":"Magalhaes","year":"2018","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2026.128680_bb0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.actatropica.2018.09.003","article-title":"A scoping review of Chikungunya virus infection: epidemiology, clinical characteristics, viral co-circulation complications, and control","volume":"188","author":"Silva","year":"2018","journal-title":"Acta Trop"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128680_bb0055","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.stem.2016.02.016","article-title":"Zika virus infects human cortical neural progenitors and attenuates their growth","volume":"18","author":"Tang","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.vaccine.2026.128680_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/srep41389","article-title":"Primary human placental trophoblasts are permissive for Zika virus (ZIKV) replication","volume":"7","author":"Aagaard","year":"2017","journal-title":"Sci Rep"},{"issue":"17","key":"10.1016\/j.vaccine.2026.128680_bb0065","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1128\/JVI.00354-15","article-title":"Biology of Zika virus infection in human skin cells","volume":"89","author":"Hamel","year":"2015","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128680_bb0070","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.cell.2016.04.032","article-title":"Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure","volume":"165","author":"Qian","year":"2016","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128680_bb0075","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMoa1600651","article-title":"Zika virus associated with microcephaly","volume":"374","author":"Mlakar","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128680_bb0080","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240694","article-title":"Fetal MAVS and type I IFN signaling pathways control ZIKV infection in the placenta and maternal decidua","volume":"221","author":"Alippe","year":"2024","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128680_bb0085","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.15252\/embr.201642627","article-title":"Zika virus inhibits type-I interferon production and downstream signaling","volume":"17","author":"Kumar","year":"2016","journal-title":"EMBO Rep"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128680_bb0090","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.7150\/ijbs.83056","article-title":"Targeting type I interferon induction and signaling: how Zika virus escapes from host innate immunity","volume":"19","author":"Hu","year":"2023","journal-title":"Int J Biol Sci"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128680_bb0095","doi-asserted-by":"crossref","first-page":"9927","DOI":"10.1007\/s12035-023-03704-1","article-title":"Interplay between Zika virus-induced autophagy and neural stem cell fate determination","volume":"61","author":"Bindu","year":"2024","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.vaccine.2026.128680_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.microb.2024.100180","article-title":"The role of microglia in Zika virus pathogenesis: possible diagnostic and therapeutic strategies","volume":"5","author":"Paul","year":"2024","journal-title":"The Microbe"},{"issue":"10027","key":"10.1016\/j.vaccine.2026.128680_bb0105","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain-Barr\u00e9 syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study","volume":"387","author":"Cao-Lormeau","year":"2016","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.vaccine.2026.128680_bb0110","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1605564","article-title":"Guillain-Barr\u00e9 syndrome associated with Zika virus infection in Colombia","volume":"375","author":"Parra","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128680_bb0115","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-021-00778-8","article-title":"Chikungunya virus infection: molecular biology, clinical characteristics, and epidemiology in Asian countries","volume":"28","author":"Khongwichit","year":"2021","journal-title":"J Biomed Sci"},{"issue":"Pt 8","key":"10.1016\/j.vaccine.2026.128680_bb0120","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1099\/vir.0.83628-0","article-title":"A226V mutation in virus during the 2007 Chikungunya outbreak in Kerala, India","volume":"89","author":"Kumar","year":"2008","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2026.128680_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-09771-9","article-title":"Clinical and molecular epidemiology of Chikungunya outbreaks during 2019\u20132022 in India","volume":"15","author":"Babu N","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128680_bb0130","doi-asserted-by":"crossref","unstructured":"Fox, J. M., & Diamond, M. S. (2016). Immune-mediated protection and pathogenesis of Chikungunya virus. J Immunol, 197(11), 4210\u20134218. Doi;https:\/\/doi.org\/10.4049\/jimmunol.1601426.","DOI":"10.4049\/jimmunol.1601426"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128680_bb0135","article-title":"Acute immunological biomarkers for predicting chronic rheumatologic disease after Chikungunya virus infection","volume":"10","author":"Lozano-Parra","year":"2025","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128680_bb0140","doi-asserted-by":"crossref","unstructured":"Chang, A. Y., Tritsch, S., Reid, S. P., Martins, K., Encinales, L., Pacheco, N., Amdur, R. L., Porras-Ramirez, A., Rico-Mendoza, A., Li, G., Peng, J., Firestein, G. S., Simon, G. L., & Bethony, J. M. (2018). The cytokine profile in acute Chikungunya infection is predictive of chronic arthritis 20 months post infection. Diseases (Basel, Switzerland), vol. 6(4), 95. doi;https:\/\/doi.org\/10.3390\/diseases6040095.","DOI":"10.3390\/diseases6040095"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128680_bb0145","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/infdis\/jiq042","article-title":"Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor","volume":"203","author":"Chow","year":"2011","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128680_bb0150","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI84417","article-title":"Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies","volume":"127","author":"Silva","year":"2017","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128680_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines13080856","article-title":"Toll-like receptor (TLR) response in Chikungunya virus infection: mechanism of activation, immune evasion, and use of TLR agonists in vaccine development","volume":"13","author":"Kayesh","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.128680_bb0160","doi-asserted-by":"crossref","unstructured":"Hoarau, J. J., Jaffar Bandjee, M. C., Krejbich Trotot, P., Das, T., Li-Pat-Yuen, G., Dassa, B., Denizot, M., Guichard, E., Ribera, A., Henni, T., Tallet, F., Moiton, M. P., Gauz\u00e8re, B. A., Bruniquet, S., Jaffar Bandjee, Z., Morbidelli, P., Martigny, G., Jolivet, M., Gay, F., Grandadam, M., \u2026 Gasque, P. (2010). Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol, 184(10), 5914\u20135927. Doi;https:\/\/doi.org\/10.4049\/jimmunol.0900255.","DOI":"10.4049\/jimmunol.0900255"},{"key":"10.1016\/j.vaccine.2026.128680_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1240860","article-title":"Co-circulation of Chikungunya virus, Zika virus, and serotype 1 of Dengue virus in Western Bahia, Brazil","volume":"14","author":"de Fran\u00e7a Cirilo","year":"2023","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2026.128680_bb0170","doi-asserted-by":"crossref","unstructured":"Silva, M. M. O., Tauro, L. B., Kikuti, M., Anjos, R. O., Santos, V. C., Gon\u00e7alves, T. S. F., Paploski, I. A. D., Moreira, P. S. S., Nascimento, L. C. J., Campos, G. S., Ko, A. I., Weaver, S. C., Reis, M. G., Kitron, U., & Ribeiro, G. S. (2019). Concomitant transmission of Dengue, Chikungunya, and Zika viruses in Brazil: clinical and epidemiological findings from surveillance for acute febrile illness. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 69(8), 1353\u20131359. Doi;https:\/\/doi.org\/10.1093\/cid\/ciy1083, Clin Infect Dis.","DOI":"10.1093\/cid\/ciy1083"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128680_bb0175","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003201","article-title":"Investigation into an outbreak of dengue-like illness in Pernambuco, Brazil, revealed a cocirculation of Zika, Chikungunya, and Dengue virus type 1","volume":"95","author":"Pess\u00f4a","year":"2016","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128680_bb0180","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-020-05611-5","article-title":"Seroprevalence, spatial dispersion and factors associated with flavivirus and Chikungunya infection in a risk area: a population-based seroprevalence study in Brazil","volume":"20","author":"Barreto","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"6284","key":"10.1016\/j.vaccine.2026.128680_bb0185","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1126\/science.aaf5316","article-title":"The 3.8 \u00c5 resolution cryo-EM structure of Zika virus","volume":"352","author":"Sirohi","year":"2016","journal-title":"Science (New York, N.Y.)"},{"issue":"7603","key":"10.1016\/j.vaccine.2026.128680_bb0190","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nature17994","article-title":"Structure of the thermally stable Zika virus","volume":"533","author":"Kostyuchenko","year":"2016","journal-title":"Nature"},{"issue":"7720","key":"10.1016\/j.vaccine.2026.128680_bb0195","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41586-018-0446-y","article-title":"The emergence of Zika virus and its new clinical syndromes","volume":"560","author":"Pierson","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128680_bb0200","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.antiviral.2013.03.008","article-title":"The flavivirus NS1 protein: molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker","volume":"98","author":"Muller","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2026.128680_bb0205","doi-asserted-by":"crossref","unstructured":"Zhang, X., Xie, X., Xia, H., Zou, J., Huang, L., Popov, V. L., Chen, X., & Shi, P. Y. (2019). Zika virus NS2A-mediated virion assembly. mBio, 10(5), e02375\u201319. doi;https:\/\/doi.org\/10.1128\/mBio.02375-19.","DOI":"10.1128\/mBio.02375-19"},{"key":"10.1016\/j.vaccine.2026.128680_bb0210","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.antiviral.2015.03.014","article-title":"The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development","volume":"118","author":"Luo","year":"2015","journal-title":"Antivir Res"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128680_bb0215","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.chom.2016.05.009","article-title":"Zika virus targets human STAT2 to inhibit type I interferon signaling","volume":"19","author":"Grant","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128680_bb0220","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41422-018-0007-9","article-title":"Structural insight into the Zika virus capsid encapsulating the viral genome","volume":"28","author":"Li","year":"2018","journal-title":"Cell Res"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128680_bb0225","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jmb.2018.02.006","article-title":"Crystal structure of the capsid protein from Zika virus","volume":"430","author":"Shang","year":"2018","journal-title":"J Mol Biol"},{"issue":"36","key":"10.1016\/j.vaccine.2026.128680_bb0230","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1016\/j.vaccine.2021.07.036","article-title":"Development of a novel ZIKV vaccine comprised of immunodominant CD4+ and CD8+ T cell epitopes identified through comprehensive epitope mapping in Zika virus infected mice","volume":"39","author":"Sun","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128680_bb0235","doi-asserted-by":"crossref","unstructured":"Li, L., Lok, S. M., Yu, I. M., Zhang, Y., Kuhn, R. J., Chen, J., & Rossmann, M. G. (2008). The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science (New York, N.Y.), vol. 319(5871), 1830\u20131834. doi;https:\/\/doi.org\/10.1126\/science.1153263.","DOI":"10.1126\/science.1153263"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128680_bb0240","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrmicro1067","article-title":"A structural perspective of the flavivirus life cycle","volume":"3","author":"Mukhopadhyay","year":"2005","journal-title":"Nat Rev Microbiol"},{"issue":"16","key":"10.1016\/j.vaccine.2026.128680_bb0245","doi-asserted-by":"crossref","first-page":"8353","DOI":"10.1128\/JVI.00696-10","article-title":"Influence of pr-M cleavage on the heterogeneity of extracellular Dengue virus particles","volume":"84","author":"Junjhon","year":"2010","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128680_bb0250","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cell.2017.04.024","article-title":"Recurrent potent human neutralizing antibodies to Zika virus in Brazil and Mexico","volume":"169","author":"Robbiani","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.128680_bb0255","doi-asserted-by":"crossref","unstructured":"Dejnirattisai, W., Jumnainsong, A., Onsirisakul, N., Fitton, P., Vasanawathana, S., Limpitikul, W., Puttikhunt, C., Edwards, C., Duangchinda, T., Supasa, S., Chawansuntati, K., Malasit, P., Mongkolsapaya, J., & Screaton, G. (2010). Cross-reacting antibodies enhance dengue virus infection in humans. Science (New York, N.Y.), vol. 328(5979), 745\u2013748. doi;https:\/\/doi.org\/10.1126\/science.1185181.","DOI":"10.1126\/science.1185181"},{"key":"10.1016\/j.vaccine.2026.128680_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2018.00044","article-title":"Antibody-dependent enhancement and Zika: real threat or phantom menace?","volume":"8","author":"Mart\u00edn-Acebes","year":"2018","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2026.128680_bb0265","doi-asserted-by":"crossref","unstructured":"Yap, M. L., Klose, T., Urakami, A., Hasan, S. S., Akahata, W., & Rossmann, M. G. (2017). Structural studies of Chikungunya virus maturation. Proc Natl Acad Sci U S A, 114(52), 13703\u201313707. Doi;https:\/\/doi.org\/10.1073\/pnas.1713166114.","DOI":"10.1073\/pnas.1713166114"},{"issue":"7324","key":"10.1016\/j.vaccine.2026.128680_bb0270","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nature09555","article-title":"Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography","volume":"468","author":"Voss","year":"2010","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128680_bb0275","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/mr.58.3.491-562.1994","article-title":"The alphaviruses: gene expression, replication, and evolution","volume":"58","author":"Strauss","year":"1994","journal-title":"Microbiol Rev"},{"key":"10.1016\/j.vaccine.2026.128680_bb0280","doi-asserted-by":"crossref","unstructured":"Ahola, T., & K\u00e4\u00e4ri\u00e4inen, L. (1995). Reaction in alphavirus mRNA capping: formation of a covalent complex of nonstructural protein nsP1 with 7-methyl-GMP. Proc Natl Acad Sci U S A, 92(2), 507\u2013511. Doi;https:\/\/doi.org\/10.1073\/pnas.92.2.507.","DOI":"10.1073\/pnas.92.2.507"},{"issue":"17","key":"10.1016\/j.vaccine.2026.128680_bb0285","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01008-18","article-title":"The methyltransferase-like domain of Chikungunya virus nsP2 inhibits the interferon response by promoting the nuclear export of STAT1","volume":"92","author":"G\u00f6ertz","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128680_bb0290","doi-asserted-by":"crossref","unstructured":"Abraham, R., Hauer, D., McPherson, R. L., Utt, A., Kirby, I. T., Cohen, M. S., Merits, A., Leung, A. K. L., & Griffin, D. E. (2018). ADP-ribosyl-binding and hydrolase activities of the alphavirus nsP3 macrodomain are critical for initiation of virus replication. Proc Natl Acad Sci U S A, 115(44), E10457\u2013E10466. Doi;https:\/\/doi.org\/10.1073\/pnas.1812130115.","DOI":"10.1073\/pnas.1812130115"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128680_bb0295","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1099\/jgv.0.000249","article-title":"Alphavirus RNA synthesis and non-structural protein functions","volume":"96","author":"Rupp","year":"2015","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2026.128680_bb0300","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.virol.2017.12.020","article-title":"Structure-function insights into Chikungunya virus capsid protein: small molecules targeting capsid hydrophobic pocket","volume":"515","author":"Sharma","year":"2018","journal-title":"Virology"},{"issue":"49","key":"10.1016\/j.vaccine.2026.128680_bb0305","doi-asserted-by":"crossref","first-page":"46923","DOI":"10.1074\/jbc.M207847200","article-title":"Alphavirus 6K proteins form ion channels","volume":"277","author":"Melton","year":"2002","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128680_bb0310","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1146\/annurev-virology-031413-085521","article-title":"Mechanisms of virus membrane fusion proteins","volume":"1","author":"Kielian","year":"2014","journal-title":"Annual review of virology"},{"issue":"7324","key":"10.1016\/j.vaccine.2026.128680_bb0315","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nature09546","article-title":"Structural changes of envelope proteins during alphavirus fusion","volume":"468","author":"Li","year":"2010","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.vaccine.2026.128680_bb0320","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1016\/j.cell.2021.07.006","article-title":"Pan-protective anti-alphavirus human antibodies target a conserved E1 protein epitope","volume":"184","author":"Kim","year":"2021","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128680_bb0325","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.cell.2015.10.050","article-title":"Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress","volume":"163","author":"Fox","year":"2015","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128680_bb0330","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni.3515","article-title":"Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus","volume":"17","author":"Dejnirattisai","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2026.128680_bb0335","doi-asserted-by":"crossref","unstructured":"Priyamvada, L., Quicke, K. M., Hudson, W. H., Onlamoon, N., Sewatanon, J., Edupuganti, S., Pattanapanyasat, K., Chokephaibulkit, K., Mulligan, M. J., Wilson, P. C., Ahmed, R., Suthar, M. S., & Wrammert, J. (2016). Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A, 113(28), 7852\u20137857. Doi;https:\/\/doi.org\/10.1073\/pnas.1607931113.","DOI":"10.1073\/pnas.1607931113"},{"key":"10.1016\/j.vaccine.2026.128680_bb0340","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijbiomac.2022.07.028","article-title":"Generation of soluble, cleaved, well-ordered, native-like dimers of Dengue virus 4 envelope protein ectodomain (sE) suitable for vaccine immunogen design","volume":"217","author":"Chiranjivi","year":"2022","journal-title":"Int J Biol Macromol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128680_bb0345","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.cell.2015.10.050","article-title":"Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress","volume":"163","author":"Fox","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.128680_bb0350","doi-asserted-by":"crossref","unstructured":"Verma, A., Nayak, K., Chandele, A., Singla, M., Ratageri, V. H., Lodha, R., Kabra, S. K., Murali-Krishna, K., & Ray, P. (2021). Chikungunya-specific IgG and neutralizing antibody responses in natural infection of Chikungunya virus in children from India. Arch Virol, 166(7), 1913\u20131920. Doi;https:\/\/doi.org\/10.1007\/s00705-021-05049-3.","DOI":"10.1007\/s00705-021-05049-3"},{"key":"10.1016\/j.vaccine.2026.128680_bb0355","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41579-018-0039-7","article-title":"Zika virus vaccines","volume":"16","author":"Abbink","year":"2018","journal-title":"Nat Rev Microbiol"},{"issue":"10120","key":"10.1016\/j.vaccine.2026.128680_bb0360","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(17)33105-7","article-title":"Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials","volume":"391","author":"Gaudinski","year":"2018","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128680_bb0365","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1708120","article-title":"Safety and immunogenicity of an anti-Zika virus DNA vaccine","volume":"385","author":"Tebas","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.vaccine.2026.128680_bb0370","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310517","article-title":"Heterologous DNA prime- subunit protein boost with Chikungunya virus E2 induces neutralizing antibodies and cellular-mediated immunity","volume":"24","author":"Coirada","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2026.128680_bb0375","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.virol.2016.01.009","article-title":"Next generation sequencing of DNA-launched chikungunya vaccine virus","volume":"490","author":"Hidajat","year":"2016","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128680_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/v13030382","article-title":"Multivalent DNA vaccines as a strategy to combat multiple concurrent epidemics: mosquito-borne and hemorrhagic fever viruses","volume":"13","author":"Jiang","year":"2021","journal-title":"Viruses"},{"issue":"27","key":"10.1016\/j.vaccine.2026.128680_bb0385","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1016\/j.vaccine.2018.05.095","article-title":"A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections","volume":"36","author":"Chattopadhyay","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128680_bb0390","doi-asserted-by":"crossref","unstructured":"Prow, N. A., Liu, L., Nakayama, E., Cooper, T. H., Yan, K., Eldi, P., Hazlewood, J. E., Tang, B., Le, T. T., Setoh, Y. X., Khromykh, A. A., Hobson-Peters, J., Diener, K. R., Howley, P. M., Hayball, J. D., & Suhrbier, A. (2018). A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses. Nature communications, 9(1), 1230. Doi;https:\/\/doi.org\/10.1038\/s41467-018-03662-6.","DOI":"10.1038\/s41467-018-03662-6"},{"issue":"13","key":"10.1016\/j.vaccine.2026.128680_bb0395","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202303619","article-title":"A divalent Chikungunya and Zika nanovaccine with thermostable self-assembly multivalent scaffold LS-SUMO","volume":"13","author":"Li","year":"2024","journal-title":"Adv Healthc Mater"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128680_bb0400","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1084\/jem.20090247","article-title":"Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant","volume":"206","author":"Longhi","year":"2009","journal-title":"J Exp Med"},{"issue":"47","key":"10.1016\/j.vaccine.2026.128680_bb0405","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1016\/j.vaccine.2014.09.036","article-title":"Vaccination with liposomal poly(I:C) induces discordant maturation of migratory dendritic cell subsets and anti-viral gene signatures in afferent lymph cells","volume":"32","author":"Neeland","year":"2014","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128680_bb0410","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1073\/pnas.0711976105","article-title":"The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine","volume":"105","author":"Trumpfheller","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2026.128680_bb0415","doi-asserted-by":"crossref","unstructured":"Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004). Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science (New York, N.Y.), vol. 303(5663), 1529\u20131531. doi;https:\/\/doi.org\/10.1126\/science.1093616.","DOI":"10.1126\/science.1093616"},{"key":"10.1016\/j.vaccine.2026.128680_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112816","article-title":"Evaluation of the adjuvant effect of imiquimod and CpG ODN 1826 in chimeric DNA vaccine against Japanese encephalitis","volume":"140","author":"Zang","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128680_bb0425","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1006\/cimm.1999.1572","article-title":"Immunostimulatory DNA pre-priming: a novel approach for prolonged Th1-biased immunity","volume":"198","author":"Kobayashi","year":"1999","journal-title":"Cell Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128680_bb0430","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128680_bb0435","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1189\/jlb.0305172","article-title":"The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells","volume":"78","author":"Thompson","year":"2005","journal-title":"J Leukoc Biol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128680_bb0440","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/vaccines2020323","article-title":"Immune adjuvant effect of molecularly-defined toll-like receptor ligands","volume":"2","author":"Toussi","year":"2014","journal-title":"Vaccines"},{"issue":"34","key":"10.1016\/j.vaccine.2026.128680_bb0445","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1016\/j.vaccine.2022.07.018","article-title":"Evaluation of monophosphoryl lipid A as an adjuvanted for inactivated Chikungunya virus","volume":"40","author":"Gosavi","year":"2022","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128680_bb0450","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines7040161","article-title":"Effects of adjuvants on the immunogenicity and efficacy of a Zika virus envelope domain III subunit vaccine","volume":"7","author":"Wang","year":"2019","journal-title":"Vaccines"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128680_bb0455","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1080\/21645515.2017.1330236","article-title":"Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity","volume":"13","author":"Suschak","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128680_bb0460","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.antiviral.2018.09.014","article-title":"The genetic adjuvant IL-12 enhances the protective efficacy of a DNA vaccine for Venezuelan equine encephalitis virus delivered by intramuscular injection in mice","volume":"159","author":"Suschak","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2026.128680_bb0465","doi-asserted-by":"crossref","unstructured":"Perales, M. A., Yuan, J., Powel, S., Gallardo, H. F., Rasalan, T. S., Gonzalez, C., Manukian, G., Wang, J., Zhang, Y., Chapman, P. B., Krown, S. E., Livingston, P. O., Ejadi, S., Panageas, K. S., Engelhorn, M. E., Terzulli, S. L., Houghton, A. N., & Wolchok, J. D. (2008). Phase I\/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Molecular therapy : the journal of the American Society of Gene Therapy, 16(12), 2022\u20132029. doi;https:\/\/doi.org\/10.1038\/mt.2008.196, Mol Ther.","DOI":"10.1038\/mt.2008.196"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128680_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102536","article-title":"Genetic adjuvants: a paradigm shift in vaccine development and immune modulation","volume":"36","author":"Spunde","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.vaccine.2026.128680_bb0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21775\/cimb.022.001","article-title":"Systems vaccinology applied to DNA vaccines: perspective and challenges","volume":"22","author":"Lever","year":"2017","journal-title":"Curr Issues Mol Biol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128680_bb0480","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/vaccines3020320","article-title":"Vaccine adjuvants: from 1920 to 2015 and beyond","volume":"3","author":"Di Pasquale","year":"2015","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128680_bb0485","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The history of MF59(\u00ae) adjuvant: a phoenix that arose from the ashes","volume":"12","author":"O\u2019Hagan","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128680_bb0490","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128680_bb0495","article-title":"Immunization with DNA prime-subunit protein boost strategy based on influenza H9N2 virus conserved matrix protein M1 and its epitope screening","volume":"10","author":"Liu","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128680_bb0500","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/vaccines7020042","article-title":"Designed DNA-encoded IL-36 gamma acts as a potent molecular adjuvant enhancing Zika synthetic DNA vaccine-induced immunity and protection in a lethal challenge model","volume":"7","author":"Louis","year":"2019","journal-title":"Vaccines"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128680_bb0505","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113605","article-title":"DNA vaccines-how far from clinical use?","volume":"19","author":"Hobernik","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128680_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12010071","article-title":"DNA vaccines: their formulations, engineering and delivery","volume":"12","author":"Kozak","year":"2024","journal-title":"Vaccines"},{"issue":"40","key":"10.1016\/j.vaccine.2026.128680_bb0515","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1016\/j.vaccine.2009.07.005","article-title":"Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery","volume":"27","author":"Best","year":"2009","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.vaccine.2026.128680_bb0520","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.vaccine.2008.02.033","article-title":"The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods","volume":"26","author":"Wang","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128680_bb0525","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-022-00469-x","article-title":"A DNA vaccine targeting VEE virus delivered by needle-free jet-injection protects macaques against aerosol challenge","volume":"7","author":"Suschak","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128680_bb0530","article-title":"The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects","volume":"15","author":"Lu","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128680_bb0535","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-65059-0","article-title":"Lipid nanoparticle formulation increases efficiency of DNA-vectored vaccines\/immunoprophylaxis in animals including transchromosomic bovines","volume":"10","author":"Mucker","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128680_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101169","article-title":"Lipid nanoparticle-encapsulated DNA vaccine robustly induce superior immune responses to the mRNA vaccine in Syrian hamsters","volume":"32","author":"Liao","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128680_bb0545","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00283-24","article-title":"Lipid nanoparticle-encapsulated DNA vaccine confers protection against swine and human-origin H1N1 influenza viruses","volume":"9","author":"Nguyen","year":"2024","journal-title":"mSphere"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128680_bb0550","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1128\/JVI.02757-13","article-title":"In vivo electroporation of minicircle DNA as a novel method of vaccine delivery to enhance HIV-1-specific immune responses","volume":"88","author":"Wang","year":"2014","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128680_bb0555","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.7150\/thno.23438","article-title":"Efficient delivery of nucleic acid molecules into skin by combined use of microneedle roller and flexible interdigitated electroporation array","volume":"8","author":"Huang","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.vaccine.2026.128680_bb0560","article-title":"Enhanced immunogenicity and protective efficacy in mice following a Zika DNA vaccine designed by modulation of membrane-anchoring regions and its association to adjuvants","volume":"15","author":"Teixeira","year":"2024","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128680_bb0565","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1080\/21645515.2015.1035502","article-title":"DNA vaccines, electroporation and their applications in cancer treatment","volume":"11","author":"Lee","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128680_bb0570","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/gt.2009.140","article-title":"DNA prime\u2013protein boost increased the titer, avidity and persistence of anti-A\u03b2 antibodies in wild-type mice","volume":"17","author":"Davtyan","year":"2010","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2026.128680_bb0575","doi-asserted-by":"crossref","first-page":"17","DOI":"10.21775\/cimb.022.017","article-title":"Molecular adjuvants for DNA vaccines","volume":"22","author":"Li","year":"2017","journal-title":"Curr Issues Mol Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128680_bb0580","doi-asserted-by":"crossref","DOI":"10.1186\/s12985-025-02878-5","article-title":"Humoral and cellular immune response to a single dose of a novel bivalent recombinant adenovirus-vector vaccine against West Nile virus and chikungunya virus in mice","volume":"22","author":"Chang","year":"2025","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2026.128680_bb0585","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bpobgyn.2021.02.002","article-title":"Vaccines - safety in pregnancy","volume":"76","author":"Arora","year":"2021","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128680_bb0590","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines7020037","article-title":"A comparison of plasmid DNA and mRNA as vaccine technologies","volume":"7","author":"Liu","year":"2019","journal-title":"Vaccines"},{"issue":"10008","key":"10.1016\/j.vaccine.2026.128680_bb0595","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"issue":"519","key":"10.1016\/j.vaccine.2026.128680_bb0600","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1673","article-title":"Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial","volume":"11","author":"Kallas","year":"2019","journal-title":"Sci Transl Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T22:27:43Z","timestamp":1783290463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26004883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":120,"alternative-id":["S0264410X26004883"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128680","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies to enhance DNA vaccine efficacy against emerging arboviruses: lessons from ZIKA and Chikungunya viruses","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128680","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128680"}}